Precigen, Inc. (PGEN) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -2588.2%, revenue growth 6322.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $9.68M |
| Revenue (TTM) | $0.1B |
| Net Margin | -2588.2% |
| Return on Equity | -157.5% |
| Operating Margin (TTM) | -46.1% |
| Debt / Equity | 2.15 |
| Current Ratio | 4.58 |
| Net Debt / EBITDA | -2.2 |
| Revenue Growth (YoY) | 6322.7% |
| EPS Growth (YoY) | -166.7% |
| FCF Growth (YoY) | -8.7% |
| Price / Book | 56.28 |
| Price / Sales | 30.49 |
| FCF Yield | -3.7% |
| Altman Z-Score | -11.95 (distress) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
PGEN overview · PGEN earnings · PGEN KPIs · PGEN documents · PGEN ownership · PGEN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.